Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension
5 affiliations
- 1Division of Critical Care Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
- 2Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
- 3Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA
- 4Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA
- 5Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA
Abstract
Background: Glucagon-like peptide-1 (GLP-1) agonists are becoming widely used, but commonly cause gastrointestinal side effects that are often mild but can occasionally be significant.
Case Summary: A 35-year-old male patient with obesity and otherwise minimal medical history presented to the emergency department after a syncopal episode that occurred several days after restarting high-dose GLP-1 agonist therapy. Imaging showed massive gastric distension with significant inferior vena cava compression. He developed low-output shock requiring very high-dose vasoactive medications, which resolved after gastric decompression via emesis, nasogastric tube placement, and intravenous fluid resuscitation.
Discussion: This case represents a heretofore unseen side effect of glucagon-like peptide-1 receptor agonist administration, with initiation of maximum-dose semaglutide leading to dramatic gastric distension causing inferior vena cava compression and low-output shock.
Take-Home Messages: In patients with unexplained hypotension, shock, and/or syncope on glucagon-like peptide-1 agonist therapy, adverse medication effects should be considered as possible etiologies. This case emphasizes the importance of gradual dose escalation of glucagon-like peptide-1 agonists under provider guidance.
Related
- Complex Cardiac Tumor with Concomitant Pericardial Effusion and Hemodynamic Compromise in a Septuagenarian: Case Report of Anesthetic and Surgical Considerations
- A nurse-led standardized bedside gastric ultrasound monitoring protocol for abdominal distension management in critically ill patients receiving enteral nutrition: a pragmatic, exploratory randomized controlled trial.
- Mechanical and Hemodynamic Effects of Balloon-Expandable and Self-Expanding Stents in a Saccular Abdominal Aortic Aneurysm Model: Fluid–Structure Interaction Analyses
- Comparison of intraoperative hemodynamic changes and recovery outcomes between non-menopausal and postmenopausal women undergoing total abdominal hysterectomy under general anesthesia.
- Artificial intelligence-based surrogate modeling of hemodynamic indicators in abdominal aortic aneurysms using computational fluid dynamics
BibTeX
@article{amdahl2026hemodynamic,
title = {{Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension}},
author = {Matthew B. Amdahl and Vishwesh Bharadiya and Brian Obritsch and Obadi Obadi and Matthew Y. Wong and Matthew M. Rode and Jeahan Colletti and Gustavo A. Cortes Puentes and James Chen and Garima Dahiya},
journal = {JACC Case Reports},
year = {2026},
month = sep,
doi = {10.1016/j.jaccas.2026.110452},
url = {https://doi.org/10.1016/j.jaccas.2026.110452},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension
AU - Matthew B. Amdahl
AU - Vishwesh Bharadiya
AU - Brian Obritsch
AU - Obadi Obadi
AU - Matthew Y. Wong
AU - Matthew M. Rode
AU - Jeahan Colletti
AU - Gustavo A. Cortes Puentes
AU - James Chen
AU - Garima Dahiya
PY - 2026
DA - 2026/09/30
JO - JACC Case Reports
DO - 10.1016/j.jaccas.2026.110452
UR - https://doi.org/10.1016/j.jaccas.2026.110452
AB - Background: Glucagon-like peptide-1 (GLP-1) agonists are becoming widely used, but commonly cause gastrointestinal side effects that are often mild but can occasionally be significant. Case Summary: A 35-year-old male patient with obesity and otherwise minimal medical history presented to the emergency department after a syncopal episode that occurred several days after restarting high-dose GLP-1 agonist therapy. Imaging showed massive gastric distension with significant inferior vena cava compression. He developed low-output shock requiring very high-dose vasoactive medications, which resolved after gastric decompression via emesis, nasogastric tube placement, and intravenous fluid resuscitation. Discussion: This case represents a heretofore unseen side effect of glucagon-like peptide-1 receptor agonist administration, with initiation of maximum-dose semaglutide leading to dramatic gastric distension causing inferior vena cava compression and low-output shock. Take-Home Messages: In patients with unexplained hypotension, shock, and/or syncope on glucagon-like peptide-1 agonist therapy, adverse medication effects should be considered as possible etiologies. This case emphasizes the importance of gradual dose escalation of glucagon-like peptide-1 agonists under provider guidance.
SN - 2666-0849
ER -